Additional information
White Powder
265989-44-4
ACI-011225
208.2-209.0°C
C33H34FN2NaO6
596.62
Ambient
2-8°C
Cardiovascular
Pharmaceutical Impurity Standards
(ßR,dR)-2-(4-fluorophenyl)-ß,d-dihydroxy-4-[[(4-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-1H-Pyrrole-1-heptanoic acid sodium salt
(ßR,dR)-2-(4-fluorophenyl)-ß,d-dihydroxy-4-[[(4-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-1H-Pyrrole-1-heptanoic acid sodium salt
4-Hydroxy atorvastatin






![Ethyl (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethylsulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate](https://staging.analyticachemie.in/wp-content/uploads/1A06130-150x150.png)


![2-sec-butyl-4-{4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl}-2H-1,2,4-triazol-3(4H)-one](https://staging.analyticachemie.in/wp-content/uploads/1A06380-150x110.png)
![Abiraterone Isopropyl Ether (25 mg) (3-((3S,8R,9S,10R,13S,14S)-3-isopropoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridine; 3beta-Isopropoxy-17-(pyridin-3-yl)androsta-5,16-diene)](https://staging.analyticachemie.in/wp-content/uploads/image-1-150x145.png)